To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational ...

The current regulatory environment in the U.S. tolerates overly large PBMs that engage in anticompetitive practices to accumulate excessive profits. Without strong competitors, dominant PBMs are free ...

Groundbreaking weight-loss drugs like Ozempic and Wegovy have understandably generated a lot of excitement, bringing hope to ...

In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

Can the new strategy achieve the great shift Reed has called for, or is the process doomed to failure from the start?